November 10, 2026 · Endoscopy · DOI: 10.1055/a-2999-9638

Phase I Trial of Liquid Nitrogen Spray Cryotherapy concurrent with neoadjuvant chemoradiation for Locally Advanced Esophageal Cancer: Dose Escalation and Long-Term Overall Survival.

Listen to this summary

This phase 1 "3+3" dose-escalation trial asked whether liquid nitrogen spray cryotherapy (LNSC) given before and during neoadjuvant chemoradiation is safe for locally advanced esophageal cancer. No grade 2 or 3 treatment-related adverse events occurred, the maximum tolerated dose was 3 sessions (2 before and 1 during chemoradiation), and 70% of patients achieved complete clinical response, with 40% overall survival at a median follow-up of 36 months. The authors conclude that the regimen is safe and promising enough to justify a phase 2 trial, though the small sample size (n=13) limits these conclusions.

Tilak Shah, Tilak Shah, Joseph Spataro, Pritesh Mutha, Bhaumik Patel

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play